|
|
||||||||
Published online before print October 21, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,
,
,
*Laboratory for Experimental Immunology, Academic Medical Centre, University of Amsterdam, The Netherlands; and
Sir William Dunn School of Pathology, University of Oxford, United Kingdom
@ To whom correspondence should be addressed. E-mail: j.hamann{at}amc.uva.nl.
| Abstract |
|---|
The epidermal growth factor (EGF)-seven-span transmembrane receptors CD97 and EGF-like module-containing mucin-like receptor protein (EMR)2 are heptahelical molecules predominantly expressed on leukocytes. A characteristic of these receptors is their ability to interact with cellular ligands via the N-terminal EGF-like domains. The first two EGF domains of CD97 (but not EMR2) bind CD55 (decay-accelerating factor), and the fourth EGF domain of CD97 and EMR2 interacts with the glycosaminoglycan chondroitin sulfate (CS). Using fluorescent beads coated with soluble recombinant CD97 and EMR2 protein and isoform-specific monoclonal antibodies, we have determined the cellular and molecular characteristics of the interaction with CS. The fourth EGF domain of CD97 and EMR2 is expressed on activated lymphocytes and myeloid cells, whereas the ligand is specifically found on B cells within the peripheral blood. The interaction between CD97/EMR2 and CS may therefore play a role in the interaction of activated T cells, dendritic cells, and macrophages with B cells.
Key Words: B cell EGF-like domain ligand specificity multivalent probe proteoglycan
This article has been cited by other articles:
![]() |
H. Veninga, S. Becker, R. M. Hoek, M. Wobus, E. Wandel, J. van der Kaa, M. van der Valk, A. F. de Vos, H. Haase, B. Owens, et al. Analysis of CD97 Expression and Manipulation: Antibody Treatment but Not Gene Targeting Curtails Granulocyte Migration J. Immunol., November 1, 2008; 181(9): 6574 - 6583. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van Pel, H. Hagoort, J. Hamann, and W. E. Fibbe CD97 is differentially expressed on murine hematopoietic stem-and progenitor-cells Haematologica, August 1, 2008; 93(8): 1137 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yona, H.-H. Lin, P. Dri, J. Q. Davies, R. P. G. Hayhoe, S. M. Lewis, S. E. M. Heinsbroek, K. A. Brown, M. Perretti, J. Hamann, et al. Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function FASEB J, March 1, 2008; 22(3): 741 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. M. Abbott, I. Spendlove, P. Roversi, H. Fitzgibbon, V. Knott, P. Teriete, J. M. McDonnell, P. A. Handford, and S. M. Lea Structural and Functional Characterization of a Novel T Cell Receptor Co-regulatory Protein Complex, CD97-CD55 J. Biol. Chem., July 27, 2007; 282(30): 22023 - 22032. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matmati, W. Pouwels, R. van Bruggen, M. Jansen, R. M. Hoek, A. J. Verhoeven, and J. Hamann The human EGF-TM7 receptor EMR3 is a marker for mature granulocytes J. Leukoc. Biol., February 1, 2007; 81(2): 440 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Kwakkenbos, M. Matmati, O. Madsen, W. Pouwels, Y. Wang, R. E. Bontrop, P. J. Heidt, R. M. Hoek, and J. Hamann An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2 FASEB J, December 1, 2006; 20(14): 2582 - 2584. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |